Compare Intel Corp (INTC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Novo Nordisk A/S — how do they compare? Intel Corp trades at $101.08 (market cap $492.85B), while Novo Nordisk A/S trades at $46.45 (market cap $207.85B). The key difference: Intel Corp is far larger — about 2.4× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| INTC | NVO | |
|---|---|---|
Market Cap | $492.85B | $207.85B |
Volume | 43,552,012 | — |
Sector | Technology | Health |
52-Week High | $140.94 | $63.98 |
52-Week Low | $21.81 | $35.29 |
Enterprise Value | $513.66B | $222.55B |
Dividend Yield | 2.24% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $102.74, up 5.35% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings beats in Q1 and Q2 2026 highlight improving operational performance, though net income remains negative. The company is raising $20 billion via a stock offering to fund AI and foundry expansion, driving investor focus on growth prospects amid margin challenges.
Outlook: Intel's revenue growth and strategic investments in AI present upside potential, but shareholder dilution from the equity raise and persistent negative margins pose risks. Analyst consensus is mixed with a $116.67 price target, suggesting cautious optimism for the turnaround story.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
